Relapsed or Refractory Acute Myeloid Leukemia: Venetoclax and Alvocidib
Brief description of study
If you have been diagnosed with relapsed/refractory acute myeloid leukemia, you may qualify for this study. The main goal of this study is to see if the study drugs, venetoclax and alvocidib, can be safely combined for the treatment of patients with relapsed or refractory acute myeloid leukemia and produce meaningful anti-leukemia activity for patients.
Clinical Study Identifier: s18-00027
ClinicalTrials.gov Identifier: NCTs18-00027
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.